Established skincare house rebuilt its collagen-support line around a tighter Matrixyl spec in 9 weeks

Challenge

The skincare house's R&D group had been formulating with Palmitoyl Pentapeptide-4 from a generalist ingredient distributor for several years. The reformulation brief called for a tighter spec (verified ≥99.0% HPLC, documented stability in their oil-in-water emulsion carrier, batch-level INCI documentation aligned with EU CPNP across the three member-state markets the line shipped into) so the marketing team could substantiate a more substantive on-pack collagen-support claim. The Head of R&D needed a supplier that could meet the spec, document it per lot, and hold the spec across recurring orders.

Approach

Pepoderma quoted cosmetic-grade Matrixyl against a 12-month forecast with the agreed spec set: HPLC at ≥99.0%, ESI-MS identity confirming the palmitoyl-conjugated mass, water content under 5%, and stability data in a reference oil-in-water emulsion across 12 months at 25°C. The first commercial lot delivered against spec on every checkpoint; the R&D group's in-house QC accepted the documentation packet without back-and-forth. Recurring lots ship against the forecast on a quarterly cadence with lot-level documentation refreshed each time.

Outcome

Total elapsed time from initial inquiry to first commercial lot delivery: 9 weeks (3 weeks qualification + 6 weeks production against forecast). The rebuilt serum and night cream launched on schedule and the marketing team's on-pack claim was supported by the documented stability data without needing a separate consumer-perception study. Subsequent quarterly lots have all delivered on first checkpoint pass with no recurring qualification overhead.